Discovery of vina-ginsenoside R18 as a novel dual-target inhibitor of dengue virus envelope protein and RNA-dependent RNA polymerase

Abstract

Dengue virus (DENV) poses a serious health threat globally for which specific antivirals are not available. Envelope (E) protein and RNA-dependent RNA polymerase (RdRp) from DENV represent the most critical targets for the development of antivirals that inhibit viral adsorption for entry and genome replication, respectively; no dual inhibitors targeting E/RdRp have been reported to date. Vina-ginsenoside R18 (R18), a triterpenoid saponin isolated from Panax notoginseng, was shown to target E protein domain III to inhibit binding of E protein to integrin beta3, thus preventing viral adsorption to the host surface receptor. R18 selectively targets RdRp protein and induces a conformational change, leading to a decrease in enzyme activity. Consequently, R18 represses DENV infection by acting at viral binding, entry, and replication stages, and attenuates the pathologic symptoms of DENV-infected ICR suckling and AG129 mice. These results showed R18 to be a novel dual E/RdRp inhibitor that can serve a potential agent against DENV infection.

Keywords

Dengue virus / Envelope protein / RNA-dependent RNA polymerase / Target / Inhibitor

References

[1] Paz-Bailey G, Adams LE, Deen J, Anderson KB, Katzelnick LC: Dengue. Lancet 2024, 403: 667-682.

[2] World Health Organization . (2023). Dengue and Severe Dengue. Retrieved from https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. Accessed May 28, 2023.

[3] Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al.: The Global Burden of Dengue: An Analysis from the Global Burden of Disease Study 2013. The Lancet Infectious Diseases 2016, 16: 712-723.

[4] Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al.: The Current and Future Global Distribution and Population at Risk of Dengue. Nature Microbiology 2019, 4: 1508-1515.

[5] Wilder-Smith A, Flasche S, Smith PG: Vaccine-attributable Severe Dengue in the Philippines. Lancet 2019, 394: 2151-2152.

[6] Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O’Brien K, Vannice K, et al.: Deliberations of the Strategic Advisory Group of Experts on Immunization on the Use of CYD-TDV Dengue Vaccine. The Lancet Infectious Diseases 2019, 19: e31-e38.

[7] Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C, et al.: Long-term Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003): 4·5-Year Results from a Phase 3, Randomised, Double-blind, Placebo-controlled Trial. The Lancet Global Health 2024, 12: e257-e270.

[8] Xie X, Zou J, Zhang X, Zhou Y, Routh AL, Kang C, et al.: Dengue NS2A Protein Orchestrates Virus Assembly. Cell Host & Microbe 2019, 26: 606-622.e8.

[9] Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC: The Envelope Glycoprotein from Tick-borne Encephalitis Virus at 2 A Resolution. Nature 1995, 375: 291-298.

[10] Martinez DR, Metz SW, Baric RS: Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection. Cell Host & Microbe 2021, 29: 13-22.

[11] Young E, Yount B, Pantoja P, Henein S, Meganck RM, McBride J, et al.: A Live Dengue Virus Vaccine Carrying a Chimeric Envelope Glycoprotein Elicits Dual DENV2-DENV4 Serotype-specific Immunity. Nature Communications 2023, 14: 1371.

[12] Issur M, Geiss BJ, Bougie I, Picard-Jean F, Despins S, Mayette J, et al.: The Flavivirus NS5 Protein is a True RNA Guanylyltransferase that Catalyzes a Two-step Reaction to form the RNA Cap Structure. RNA 2009, 15: 2340-2350.

[13] You S, Padmanabhan R: A Novel In Vitro Replication System for Dengue Virus. Initiation of RNA Synthesis at the 3′-end of Exogenous Viral RNA Templates Requires 5′- and 3′-terminal Complementary Sequence Motifs of the Viral RNA. Journal of Biological Chemistry 1999, 274: 33714-33722.

[14] Troost B, Smit JM: Recent Advances in Antiviral Drug Development Towards Dengue Virus. Current Opinion in Virology 2020, 43: 9-21.

[15] Bifani AM, Chan KWK, Borrenberghs D, Tan MJA, Phoo WW, Watanabe S, et al.: Therapeutics for Flaviviral Infections. Antiviral Research 2023, 210: 105517.

[16] De Clercq E.: Suramin: A Potent Inhibitor of the Reverse Transcriptase of RNA Tumor Viruses. Cancer Letters 1979, 8: 9-22.

[17] Yahi N, Sabatier JM, Nickel P, Mabrouk K, Gonzalez-Scarano F, Fantini J: Suramin Inhibits Binding of the V3 Region of HIV-1 Envelope Glycoprotein gp120 to Galactosylceramide, the Receptor for HIV-1 gp120 on Human Colon Epithelial Cells. Journal of Biological Chemistry 1994, 269: 24349-24353.

[18] Nance CL, Siwak EB, Shearer WT: Preclinical Development of the Green Tea Catechin, Epigallocatechin Gallate, as an HIV-1 Therapy. Journal of Allergy and Clinical Immunology 2009, 123: 459-465.

[19] Li S, Hattori T, Kodama EN: Epigallocatechin Gallate Inhibits the HIV Reverse Transcription Step. Antiviral Chemistry and Chemotherapy 2011, 21: 239-43.

[20] Yang S, Xu M, Lee EM, Gorshkov K, Shiryaev SA, He S, et al.: Emetine Inhibits Zika and Ebola Virus Infections through Two Molecular Mechanisms: Inhibiting Viral Replication and Decreasing Viral Entry. Cell Discovery 2018, 4: 31.

[21] Poh MK, Yip A, Zhang S, Priestle JP, Ma NL, Smit JM, et al.: A Small Molecule Fusion Inhibitor of Dengue Virus. Antiviral Research 2009, 84: 260-266.

[22] Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh Hle A, Farrar J, et al.: A Randomized, Double-blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients. The Journal of Infectious Diseases 2013, 207: 1442-1450.

[23] Lin CS, Lu CH, Lin TH, Kiu YT, Kan JY, Chang YJ, et al.: Inhibition of Dengue Viruses by N-methylcytisine Thio Derivatives through Targeting Viral Envelope Protein and NS2B-NS3 Protease. Bioorganic & Medicinal Chemistry Letters 2024, 99: 129623.

[24] Zheng YR, Fan CL, Chen Y, Quan JY, Shi LZ, Tian CY, et al.: Anti-inflammatory, Anti-angiogenetic and Antiviral Activities of Dammarane-type Triterpenoid Saponins from the Roots of Panax notoginseng . Food & Function 2022, 13: 3590-3602.

[25] He X, Zheng Y, Tian C, Wen T, Yang T, Yu J, et al.: Quassinoids from Eurycoma Longifolia with Antiviral Activities by Inhibiting Dengue Virus Replication. Phytomedicine 2023, 110: 154650.

[26] Huang H, He X, Shi L, Yu J, Lu Z, Cao H, et al.: Tanreqing Injection Inhibits Dengue Virus Encephalitis by Suppressing the Activation of NLRP3 Inflammasome. Chinese Medicine 2024, 19(1): 24.

[27] Cui X, Wu Y, Fan D, Gao N, Ming Y, Wang P, et al.: Peptides P4 and P7 Derived from E Protein Inhibit Entry of Dengue Virus Serotype 2 via Interacting with β3 Integrin. Antiviral Research 2018, 155: 20-27.

[28] Yu CH, Rafiq NB, Cao F, Zhou Y, Krishnasamy A, Biswas KH, et al.: Integrin-beta3 Clusters Recruit Clathrin-mediated Endocytic Machinery in the Absence of Traction Force. Nature Communications 2015, 6: 8672.

[29] Sreekanth GP: Perspectives on the Current Antiviral Developments Towards RNA-Dependent RNA Polymerase (RdRp) and Methyltransferase (MTase) Domains of Dengue Virus Non-structural Protein 5 (DENV-NS5). European Journal of Medicinal Chemistry 2023, 256: 115416.

[30] Taglialegna A: Chimeric Protection to Dengue. Nature Reviews Microbiology 2023, 21: 277.

[31] Ooi EE, Kalimuddin S: Lessons for Dengue Vaccines from a Human Challenge Study. The Lancet Infectious Diseases 2024, 24: 801-803.

[32] Malavige GN, Ogg GS: Molecular Mechanisms in the Pathogenesis of Dengue Infections. Trends in Molecular Medicine 2024, 30: 484-498.

[33] Liu CH, Chang YP, Lee JY, Chen CY, Kao WY, Lin CL, et al.: Four Weeks of Off-treatment Follow-up is Sufficient to Determine Virologic Responses at Off-treatment Week 12 in Patients with Hepatitis C Virus Infection Receiving Fixed-dose Pangenotypic Direct-acting Antivirals. Journal of Medical Virology 2024, 96: e29675.

[34] Lin W, Wang X, Zhang J, Wen C, Kang W, Mao L, et al.: A Simple, Feasible, Efficient and Safe Treatment Strategy of Sofosbuvir/Velpatasvir for Chronic HCV/HIV-1 Coinfected Patients Regardless of HCV Genotypes: A Multicenter, Open-label Study in China. The Lancet Regional Health-Western Pacific 2023, 36: 100749.

[35] Nanaware N, Banerjee A, Mullick Bagchi S, Bagchi P, Mukherjee A: Dengue Virus Infection: A Tale of Viral Exploitations and Host Responses. Viruses 2021, 13(10): 1967.

[36] Sinha S, Singh K, Ravi Kumar YS, Roy R, Phadnis S, Meena V, et al.: Dengue Virus Pathogenesis and Host Molecular Machineries. Journal of Biomedical Science 2024, 31(1): 43.

[37] Ong EZ, Budigi Y, Tan HC, Robinson LN, Rowley KJ, Winnett A, et al.: Preclinical Evaluation of VIS513, a Therapeutic Antibody Against Dengue Virus, in Non-human Primates. Antiviral Research 2017, 144: 44-47.

[38] Gunale B, Farinola N, Kamat CD, Poonawalla CS, Pisal SS, Dhere RM, et al.: An Observer-blind, Randomised, Placebo-controlled, Phase 1, Single Ascending Dose Study of Dengue Monoclonal Antibody in Healthy Adults in Australia. The Lancet Infectious Diseases 2024, 24: 639-649.

[39] Zheng B, Zhao Q, Yang W, Feng P, Xin C, Ying Y, et al.: Small-molecule Antiviral Treatments for COVID-19: A Systematic Review and Network Meta-analysis. International Journal of Antimicrobial Agents 2024, 63: 107096.

[40] Muhammad Azami NA, Takasaki T, Kurane I, Moi ML: Non-Human Primate Models of Dengue Virus Infection: A Comparison of Viremia Levels and Antibody Responses during Primary and Secondary Infection among Old World and New World Monkeys. Pathogens 2020, 9(4): 247.

[41] Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, et al.: Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients with Influenza Virus Infection. The Journal of Infectious Diseases 2020, 221: 1688-1698.

[42] Shyr ZA, Cheng YS, Lo DC, Zheng W: Drug Combination Therapy for Emerging Viral Diseases. Drug Discovery Today 2021, 26: 2367-2376.

[43] Shimizu H, Saito A, Mikuni J, Nakayama EE, Koyama H, Honma T, et al.: Discovery of a Small Molecule Inhibitor Targeting Dengue Virus NS5 RNA-dependent RNA Polymerase. PLoS Neglected Tropical Disease 2019, 13: e0007894.

[44] Jia H, Gong P: A Structure-Function Diversity Survey of the RNA-Dependent RNA Polymerases from the Positive-Strand RNA Viruses. Frontiers in Microbiology 2019, 10: 1945.

[45] Lu G, Gong P: A Structural View of the RNA-dependent RNA Polymerases from the Flavivirus Genus. Virus Research 2017, 234: 34-43.

[46] European Centre for Disease Prevention and Control, 2024. Dengue Worldwide Overview. Retrieved from https://www.ecdc.europa.eu/en/dengue-monthly.

[47] Tsai TT, Chen CL, Lin YS, Chang CP, Tsai CC, Cheng YL, et al.: Microglia Retard Dengue Virus-induced Acute Viral Encephalitis. Scientific Reports 2016, 6: 27670.

[48] Lai YC, Chuang YC, Chang CP, Lin YS, Perng GC, Wu HC, et al.: Minocycline Suppresses Dengue Virus Replication by Down-regulation of Macrophage Migration Inhibitory Factor-induced Autophagy. Antiviral Research 2018, 155: 28-38.

[49] Sreekanth GP, Chuncharunee A, Cheunsuchon B, Noisakran S, Yenchitsomanus PT, Limjindaporn T.: JNK1/2 Inhibitor Reduces Dengue Virus-induced Liver Injury. Antiviral Research 2017, 141: 7-18.

[50] Sreekanth GP, Chuncharunee A, Sirimontaporn A, Panaampon J, Noisakran S, Yenchitsomanus PT, et al.: SB203580 Modulates p38 MAPK Signaling and Dengue Virus-Induced Liver Injury by Reducing MAPKAPK2, HSP27, and ATF2 Phosphorylation. PLoS One 2016, 11: e0149486.

[51] Rathore APS, Mantri CK, Tan MW, Shirazi R, Nishida A, Aman SAB, et al.: Immunological and Pathological Landscape of Dengue Serotypes 1-4 Infections in Immune-Competent Mice. Frontiers in Immunology 2021, 12: 681950.